204
Participants
Start Date
November 30, 2013
Primary Completion Date
January 30, 2017
Study Completion Date
February 21, 2017
avatrombopag (lower baseline platelet count)
60 mg avatrombopag (3 x 20 mg tablets)
placebo (lower baseline platelet count)
60 mg placebo (3 x 20 mg matching placebo tablets)
avatrombopag (higher baseline platelet count)
40 mg avatrombopag (2 x 20 mg tablets)
placebo (higher baseline platelet count)
40 mg placebo (2 x 20 mg matching placebo tablets)
Birmingham
Phoenix
Little Rock
Coronado
Loma Linda
Denver
Miami
Maywood
Indianapolis
Kansas City
New Orleans
Baltimore
Boston
Detroit
Kansas City
New York
Statesville
Charleston
Houston
San Antonio
Charlottesville
Richmond
Seattle
Ciudad Autonoma Buenos Aires
Córdoba
Rosario
Clayton
Footscray
Melbourne
Parkville
Edegem
Ghent
Liège
Aracaju
Botucatu
Porto Alegre
Salvador
Calgary
Edmonton
Hefei
Beijing
Shijiazhuang
Nanjing
Xi'an
Xi’an
Chengdu
Hangzhou
Brno
Havířov
Ostrava
Prague
Ústí nad Labem
Nice
Clichy
Rennes
Lyon
Villejuif
Mannheim
Tübingen
Frankfurt am Main
Hanover
Bonn
Leipzig
Kiel
Hamburg
Haifa
Holon
Jerusalem
Nahariya
Petah Tikva
Ramat Gan
Rehovot
Tel Aviv
Baggiovara
Florence
Milan
Pisa
Roma
Trento
Sapporo
Nishinomiya
Morioka
Takamatsu
Yufu
Okayama
Osaka
Osaka-Sayama-shi
Iruma
Bunkyo-ku
Chiyoda City
Musashino
Setagaya-ku
Shinagawa-ku
Chiba
Niigata
Okayama
Tokushima
Wakayama
Zapopan
Monterrey
Orizaba
Mérida
Durango
Arad
Bucharest
Craiova
Iași
Sibiu
Timișoara
Kemerovo
Moscow
Saint Petersburg
Samara
L'Hospitalet de Llobregat
Cáceres
Barcelona
Girona
Madrid
Valencia
Zaragoza
Eisai Inc.
INDUSTRY